Arthritis drug access 'curbed'

In the near future, those suffering from rheumatoid arthritis will have restricted treatment options at their disposal to choose from. The National Institute for health and Clinical Excellence is in full groove to recommend the use of only one anti-TNF (anti-tumour necrosis factor alpha) drug for patients residing in England and Wales.

As per statistics, about 40,000 people who are suffering from arthritis will be impinged by this proposal because at present if an anti-TNF drug doesn’t work well in case of a patient, he can try second and third drug.

This recommendation will put a full stop on the hit and trial method of examining everything that is available in the market.

The growth of the disease can be encumbered-- which consequently plummets the physical indicators like joint pain, swelling, mobility and fatigue—with the aid of Anti-TNF therapy drugs - adalimunab, etanercept, infliximab.

All three drugs functions in dissimilar manner and require to be administered in ways that are poles apart. A drug if not administered appropriately can have deadly affect either immediately or later in life.

According to NICE, a patient should be prescribed the use of only one anti-TNF, rituximab may be given to patient in case first drug doesn’t bring out the desired improvements.

Use of all three anti-TNFs one after the other is not at all a good idea, neither medically nor financially. While rituximab is available at an economical cost of £3,000 less a year compared with the cheapest anti-TNF(as put forth by NICE).

Rob Moots, a professor of rheumatology at Liverpool University and a member of the umbrella group Arthritis and Musculoskeletal Alliance alleged that in one go it is difficult to say with full certainty which TNF will work best for a patient without trying the other two.

If this restriction is imposed , the patients will probably have to face problems like rigorous pain, higher risk of surgery and long term disability, the National Rheumatoid Arthritis Society pointed out.

"NICE are re-writing the rules of rheumatoid arthritis treatment in this country ignoring the clinical effectiveness of drugs and ignoring the views of patients and clinicians," Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society said.

NICE has raised the issue of limiting the utilization and access to anti-TNFs second time.

However, NICE remained tight-lipped on the subject of bringing to light the final document in advance, which is all set to be published soon.